Argyle Therapeutics, Inc.

	In the News
	Argyle presents two posters at the 2012 Society of Investigative Dermatology (SID) conference highlighting its new cosmetic functional ingredient (SIG1273) and novel Rx lead candidate (SIG1311). » Learn more		Lead rosacea candidate SIG990 program awarded $1M from the NIAID to continue development of this molecule. » Learn more

	Argyle Therapeutics, in collaboration with Rohto Pharmaceutical, Co., announces the launch of Arazine™ for topical use in Japan. » Learn more		Argyle Therapeutics out-licenses lead Rx molecule SIG990 to Brickell Biotech for topical treatment of rosacea. » Learn more
	Services
	In addition to in-house cosmetic and pharmaceutical development programs, Argyle can provide cosmetic claim support testing, customized assay development and analytical services for your cosmetic ingredient.. » Learn more

In the News